Chemoradiotherapy in Patients With Localised Lung Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

82 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-02-28

Study Completion Date

2012-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study compares 2 different methods of combined chemotherapy and radiotherapy for the treatment of localised lung cancer in patients not suitable for surgery.

Hypothesis(es) to be tested:

1. Vinorelbine + cisplatin + high-dose palliative radiotherapy is superior to gemcitabine + high dose palliative radiotherapy in terms of efficacy in a multi-institutional setting
2. Vinorelbine + cisplatin + high-dose palliative radiotherapy is superior to gemcitabine + high dose palliative radiotherapy in terms of feasibility in a multi-institutional setting
3. Vinorelbine + cisplatin + high-dose palliative radiotherapy has a favourable toxicity profile relative to gemcitabine + high-dose palliative radiotherapy

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Radiation Therapy With or Without Vinorelbine and Cisplatin in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer

NCT00253591

Lung Cancer

COMPLETED PHASE2/PHASE3

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer

NCT00004093

Lung Cancer

TERMINATED PHASE1/PHASE2

Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

NCT01134861

Lung Cancer

COMPLETED PHASE3

Study of Vinorelbine and Cisplatin as Induction Therapy With Radiotherapy in Patients With Unresectable NSCLC

NCT02709720

Lung Cancer

COMPLETED PHASE2

Oral Vinorelbine and Cisplatin and Concurrent Radiotherapy After Induction Chemotherapy in Locally Advanced NSCLC.

NCT00295672

Lung Neoplasm

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A third of patients with non-small cell lung cancer (NSCLC) present with Stage IIIA or IIIB disease, which is not amenable to curative resection. Single modality local therapy, either surgery or radiation, only cures a fraction of such patients.

Radical radiation is not feasible for all patients with unresectable Stage IIIA or IIIB non-small cell lung cancer, based upon the extent of the loco-regional disease or the medical state of the patient. Patients of good performance status receiving protracted high-dose palliative radiotherapy do obtain a survival benefit from this therapy. Studies have shown a survival advantage by adding chemotherapy to radical radiation therapy: but studies in the high-dose palliative radiotherapy setting are lacking. Two regimens of concurrent chemotherapy with high-dose palliative radiotherapy have been developed locally, with established MTDs. These 2 regimens do warrant a comparative assessment in a phase II trial, prior to a phase III trial against high dose palliative radiation alone (36Gy/12#/5).

This is a randomised phase II trial comprising of 2 arms for randomization as follows:

Arm A:External beam radiation, 40 Gy/20#/5 per week, Plus concurrent Vinorelbine, IV, 25mg/m2, days 1, 8, 22 and + Cisplatin 20mg/m2, IV, weekly

Arm B:External beam radiation, 30 Gy/15#/5 per week, Plus concurrentGemcitabine, 200mg (flat dose) IV days 1, 8, 15

An equal number of patients will be randomised to each arm. The randomisation will be carried out by the Princess Alexandra Trial Centre.

Patients will be assessed at baseline, weekly during treatment, and then at 3 weeks, 6 weeks and 12 weeks post treatment then 3 monthly thereafter.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non Small Cell Lung Carcinoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Vinorelbine + cisplatin + high-dose palliative radiotherapy

Group Type EXPERIMENTAL

Vinorelbine

Intervention Type DRUG

IV, 25mg/m2, days 1, 8, 22

High dose Radiotherapy

Intervention Type RADIATION

External beam radiation, 40 Gy/20#/5 per week

Cisplatin

Intervention Type DRUG

20mg/m2, IV, weekly

B

Gemcitabine + high-dose palliative radiotherapy

Group Type ACTIVE_COMPARATOR

Gemcitabine

Intervention Type DRUG

200mg (flat dose) IV days 1, 8, 15

High Dose Radiotherapy

Intervention Type RADIATION

External beam radiation, 30 Gy/15#/5 per week

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Vinorelbine

IV, 25mg/m2, days 1, 8, 22

Intervention Type DRUG

High dose Radiotherapy

External beam radiation, 40 Gy/20#/5 per week

Intervention Type RADIATION

Gemcitabine

200mg (flat dose) IV days 1, 8, 15

Intervention Type DRUG

Cisplatin

20mg/m2, IV, weekly

Intervention Type DRUG

High Dose Radiotherapy

External beam radiation, 30 Gy/15#/5 per week

Intervention Type RADIATION

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Navelbine, Vinorelbine Ebewe Radiation Gemzar, Xeloda Cisplatin Ebewe, Cisplatin Injection Radiation

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically proven non-small cell lung cancer.
* Planned high dose palliative radiation therapy for locoregional control. Examples include patients with:

1. Stage I - IIIB disease with

* disease technically unsuitable for radical therapy, or · weight loss in excess of 10%, or
* concurrent medical illness
2. Patients found to have a locally advanced thoracic disease suitable for radical therapy but on work up are found to have a FDG-PET only solitary metastasis.
* All potential patients, prior to registration, must be reviewed at a multidisciplinary lung oncology meeting attended by medical oncologists, radiation oncologists and radiologists.
* No prior radiotherapy or chemotherapy for non-small cell lung cancer.
* ECOG performance status 0, 1.
* Adequate hepatic, bone marrow and renal function.
* If patient is female of child bearing potential, she must not be pregnant or lactating. Males and females of reproductive potential must practise adequate contraception.
* Written informed consent.

Exclusion Criteria

* Patient unable to receive all therapy as an outpatient.
* Significant medical conditions which in the opinion of the investigator would compromise the planned delivery of the chemotherapy and radiotherapy or which may be potentially exacerbated by these modalities.
* History of any other cancer (except non-melanoma skin cancer or carcinoma in situ of the cervix) unless in complete remission and off all therapy for that cancer for at least 5 years.
* Receiving treatment with another investigational agent.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No